Gip/glp1 co-agonist compounds

A compound of the formula:

• X1X2EGTX6TSDX10X11X12X13LDX16X17AQX20X21X22IX24X25LIX28GX30 (SEQ ID NO:505) wherein
• X1 is selected from the group consisting of Y and R1Y;
• R1 is an Ac modification of the N-terminal amino group;
• X2 is Aib;
• X6 is selected from the group consisting of αMeF and αMeF(2F);
• X10 is selected from the group consisting of 4Pal, Y, αMeF, αMeF(2F), αMeL, αMeV, Ac4c, Ac5c, Ac6c, Bip, 1Nal, 2Nal, OMeY, hTyr, Nle, V, 4CPhe, ChG, ChA, Bzt, 2FA, 4TAA, 2TA, 3TA, and KZ1;
• X11 is selected from the group consisting of S, αMeS, Aib, G, Dap, Ac5c, and T1e;
• X12 is selected from the group consisting of I and KZ1;
• X13 is selected from the group consisting of αMeL and αMeF;
• X16 is Orn;
• X17 is selected from the group consisting of Q, I, and KZ1;
• X20 is selected from the group consisting of Aib, Orn, 4Pal, αMeF, Ac5c, and Ac6c;
• X21 is selected from the group consisting of E, KZ1, G, Orn, and 4Pal;
• X22 is selected from the group consisting of F, 2ClPhe, 3ClPhe, 2FPhe, 3FPhe, 3,5FPhe, 1Nal, 2Nal, αMeF(2F), ChA, Bzt, and αMeF;
• X24 is selected from the group consisting of D-Glu, E, G, and KZ1;
• X25 is selected from the group consisting of Y, αMeY, αMeF, and KZ1;
• X28 is selected from the group consisting of E, Orn, and KZ1;
• X30 is selected from the group consisting of G, Orn, KZ1, K(Z1)R6, OrnR2, and GR2;
• R2 is selected from the group consisting of X31, X31SSG(SEQ ID NO:5), X31SSG-R3 (SEQ ID NO:6), X31SSGX35PPPX39 (SEQ ID NO:7), X31SSGX35PPPX39R3 (SEQ ID NO:8), X31SSGX35PPPX39X40 (SEQ ID NO:9), X31SSGX35PPPX39X40R3 (SEQ ID NO:
• 10), and a modification of the c-terminal group wherein the modification is NH2;
• R6 is selected from the group consisting of PSSG(SEQ ID NO:506), PSSG-R3 (SEQ ID NO:507), PSSGX35PPPX39 (SEQ ID NO:508), PSSGX35PPPX39R3 (SEQ ID NO:509), PSSGX35PPPX39X40 (SEQ ID NO:510), PSSGX35PPPX39X40R3 (SEQ ID NO:511), and a modification of the c-terminal group wherein the modification is NH2;
• X31 is selected from the group consisting of P, and KZ1;
• X35 is selected from the group consisting of A and Orn;
• X39 is selected from the group consisting of S and Orn;
• X40 is KZ1,
• R3 is a modification of the C-terminal group, wherein the modification is NH2;
• wherein two, and only two, of X10, X12, X17, X21, X24, X25, X28, X30, X31, and X40 are KZ1 or K(Z1)R6;
• Z1 is selected from the group consisting of R5 and -R4R5;
• R4 is a linker;
• and
• R5 is a fatty acid;
• or
• a pharmaceutically acceptable salt thereof.